Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (5.179.476 €): Einzelzellige Genomik zur umfassenden Verständlichkeit einer gesunden B-Zell-Reifung und Transformation in chronische lymphatische Leukämie Hor 01.04.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Einzelzellige Genomik zur umfassenden Verständlichkeit einer gesunden B-Zell-Reifung und Transformation in chronische lymphatische Leukämie
Unbiased analyses of the molecular make up of single cells are revolutionizing our understanding of cell differentiation and cancer. Over the last years, our groups have characterized the molecular features of normal B-cell subpopulations and of pools of leukemic cells from chronic lymphocytic leukemia (CLL), the most frequent leukemia in the Western world. These analyses have revealed that CLL subtypes are related to different B-cell maturation stages, and that they can show a complex subclonal architecture. Such subclonality is dynamically modulated during the course of the disease, and has deep implications in CLL biology, clinical aggressiveness and treatment responses. In this scenario, BCLL@las aims at deciphering the origin and molecular anatomy of CLL during the entire life history of the disease by generating genetic, transcriptional and epigenetic maps of hundred-thousands of single cells across locations, time points and individuals. We plan to fulfill four major objectives: 1) To generate a comprehensive atlas of normal B-cell maturation, 2) To understand the initial steps of neoplastic transformation through the analysis of minute B-cell monoclonal proliferations in healthy individuals, 3) To decipher the cellular diversity and clonal architecture of CLL at diagnosis, and 4) To characterize the single-cell subclonal dynamics of CLL during disease evolution and treatment response. To reach these goals, BCLL@las gathers together four teams with complementary expertise in B-cell biology, clinics and pathology of CLL, genomics, transcriptomics, epigenomics, sequencing technologies, single-cell profiling and computational biology. This, together with the richness of the available CLL samples and the technical and analytical depth of BCLL@las shall lead to unprecedented insights into the origin and evolution of cancer in the precision medicine era.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Consorcio para La Explotacion del Centro Nacional de Analisis Genomico | 2.297.376 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 2.882.100 € |
| Hospital Clinic de Barcelona | 0,00 € |
Quelle: https://cordis.europa.eu/project/id/810287
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
